Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342161 | 0.86 | HDAC3 (0.43) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL4332569 | 0.86 | CYP2C19 (0.44) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL4344281 | 0.84 | NPC1 (0.41) | ALDH1A1HDAC1HDAC6KMT2AMEN1 | |
| SCHEMBL4339768 | 0.81 | CYP2D6 (0.44) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL1152604 | 0.81 | ALDH1A1 (0.37) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL4332642 | 0.80 | MAPT (0.46) | ALDH1A1HSD17B10KMT2AMEN1MAPT | |
| SCHEMBL1153640 | 0.79 | ALDH1A1 (0.38) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL1153357 | 0.79 | ALDH1A1 (0.38) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL4345728 | 0.79 | ALDH1A1 (0.42) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 | |
| SCHEMBL1153300 | 0.78 | HSD11B1 (0.38) | CYP2C19CYP2D6ALDH1A1HSD17B10HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | CYP2C19 1911/4885CYP2D6 523/4885ALDH1A1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.